Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.52 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.51 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.51 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | OGA | O60502 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.42 |
| ▸ | KDR | P35968 | 3/20 | 0.42 |
| ▸ | GRAMD1A | Q96CP6 | 1/20 | 0.41 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17635118 | 0.88 | MAPT (0.69) | MAPTDDB1CRBNPDGFRBENPP2 | |
| SCHEMBL30637861 | 0.88 | MAPT (0.69) | MAPTDDB1CRBNPDGFRBENPP2 | |
| SCHEMBL15880343 | 0.84 | MAPT (0.64) | MAPTDDB1CRBNPDGFRBENPP2 | |
| SCHEMBL3533394 | 0.84 | MAPT (0.58) | MAPTDDB1CRBNPDGFRBENPP2 | |
| SCHEMBL3530060 | 0.83 | MAPT (0.65) | MAPTDDB1CRBNPDGFRBNR1H2 | |
| SCHEMBL17620618 | 0.83 | MAPT (0.80) | MAPTPDGFRBENPP2FYNKDR | |
| SCHEMBL25574538 | 0.82 | MAPT (0.67) | MAPTDDB1CRBNPDGFRBENPP2 | |
| SCHEMBL30378007 | 0.82 | MAPT (0.67) | MAPTDDB1CRBNPDGFRBENPP2 | |
| SCHEMBL4869824 | 0.82 | MAPT (0.67) | MAPTDDB1CRBNPDGFRBENPP2 | |
| SCHEMBL3530251 | 0.82 | MAPT (0.59) | MAPTDDB1CRBNPDGFRBENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3672958-B1 | ANNULATED GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2023-08-02 | — | — | EP | disclosed |
| EP-3672958-B1 | ANNULATED GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2023-08-02 | — | — | EP | disclosed |
| US-11458140-B2 | Annulated glycosidase inhibitors | ASCENEURON SA (CH) | 2022-10-04 | — | — | US | disclosed |
| US-20200289516-A1 | ANNULATED GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2020-09-17 | — | — | US | disclosed |
| US-20200289516-A1 | ANNULATED GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2020-09-17 | — | — | US | disclosed |
| EP-3672958-A1 | ANNULATED GLYCOSIDASE INHIBITORS | Asceneuron SA (CH) | 2020-07-01 | — | — | EP | disclosed |
| WO-2019037861-A1 | ANNULATED GLYCOSIDASE INHIBITORS | Asceneuron S.A. (CH) | 2019-02-28 | — | — | WO | disclosed |
| WO-2019037861-A1 | ANNULATED GLYCOSIDASE INHIBITORS | Asceneuron S.A. (CH) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200289516-A1 | ANNULATED GLYCOSIDASE INHIBITORS | GAA, GBA3, ENGASE | MAPT 26/4885DDB1 4538/4885CRBN 3369/4885 |
| US-11458140-B2 | Annulated glycosidase inhibitors | GAA, GBA3, ENGASE | MAPT 26/4885DDB1 4538/4885CRBN 3369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.